SCNI
Scinai Immunotherapeutics Ltd.
プレマーケットデータ（自動更新なし）RVOL 0.0xDV $1,26420日平均DV $96,704?
Earnings 2026-08-2052W high -86.5%52W low +12.9%Market cap $359,095Avg volume 402K
Company Overview
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q1 | 3840.00 | $487,674 | -$1M |
| 2025 Q4 | -0.40 | $263,636 | -$2M |
| 2025 Q3 | -1.20 | $277,290 | -$2M |
| 2025 Q2 | -1.20 | $386,500 | -$2M |
| 2025 Q1 | -1.20 | $386,500 | -$1M |
| 2024 Q4 | -8.80 | $206,000 | -$1M |
|
